Cirrus’ lead program is a novel AAV gene therapy designed to restore IRAK-M, a central regulator of the eye’s immune homeostasis, so as to prevent AMD progression and preserve central vision IRAK-M levels decrease with age and more prominently in people with dry AMD, presenting an important therapeutic target to combat this leading cause of vision loss in people over 50 Seed funding will advance the lead program into IND-enabling studies and support a growing pipeline of next-generation ocular m

Oct. 01, 2025 -- Aerska, a biotechnology company aiming to redefine the treatment of neurological diseases, today announced it has raised $21 million in seed financing, co-led by Age1, Backed VC and Speedinvest, with participation from Blueyard, Lingotto (Exor), Norrsken VC, Kerna, PsyMed, Saras, and Ada Ventures. The company is developing systemically administered RNA interference (RNAi) medicines designed to silence genes that drive brain diseases. Delivering genetic medicines to the brain

Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange for equity and a 3% royalty on future net sales of dotinurad Oct. 01, 2025 -- Urica Therapeutics, Inc. (“Urica” or the “Company”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary, today announced that Crystalys Therapeutics, Inc. (“Crystalys”), in which Urica maintains an equity pos

October 1, 2025 – Athernal Bio today announced its official launch alongside £3.5 million funding from founding investor Delin Ventures. The company is focused on the development of targeted immunotherapies for high-risk clonal haematopoiesis (CH), a widespread cancer precursor condition which can lead to acute myeloid leukaemia (AML) and other haematological cancers. This new funding supports key preclinical milestones as Athernal Bio moves rapidly toward clinical trials in high-risk patient po

Sept. 26, 2025 -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04®, the company’s phase 2 Alzheimer’s candidate. “This award strongly validates our approach to Alzheimer’s

Sept. 26, 2025 -- ADvantage Therapeutics, Inc., a biotechnology company developing novel therapies for neurodegenerative diseases, today announced it has been awarded a $2.5 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute on Aging of the National Institutes of Health (NIH). This non-dilutive grant will further important research supporting AD04®, the company’s phase 2 Alzheimer’s candidate. “This award strongly validates our approach to Alzheimer’s

Sept. 24, 2025 -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the close of a $95 million Series B financing. The round was co-led by RA Capital Management and Forbion with participation from existing investors including OrbiMed, RiverVest, and US Venture Partners. In conjunction with the financing, Zach Scheiner from RA and Nanna Lüneborg from Forbion have joined Sparrow’s Board of Directors. The proceeds will support development of the company’s l

Sept. 23, 2025 -- SEED Therapeutics, Inc. (“SEED”), a clinical-stage biotechnology company pioneering rational molecular glue degraders for historically undruggable disease drivers, today announced the successful completion of its $30 million Series A-3 financing, alongside U.S. Food and Drug Administration (FDA) clearance of its Investigational New Drug (IND) application for its lead program targeting RBM39. The company anticipates entering first-in-human clinical trials of ST-01156 in Q1 2026

Sept. 23, 2025 -- Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced today that the National Institutes of Health (NIH) awarded Trethera a $1.8 million grant for preclinical studies of TRE-515 as a Crohn’s disease treatment. Trethera’s lead drug candidate, TRE-515, is a once-daily oral therapy that inhibits deoxycytidine kinase (dCK), an enzyme critical to the deoxyribonucleoside salvage

Sept. 22, 2025 -- Yatiri Bio Inc. today announced it has received a grant from the Gates Foundation to launch a one-year project, Proteomics Interoperability, aimed at improving how large-scale proteomics data can be integrated and applied to global health challenges. Proteomics, the large-scale study of proteins, has emerged as a cornerstone of modern drug discovery, driving the search for new drug targets, early detection biomarkers, and measures of treatment efficacy. However, the field fac